Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
Produktmerkmale
This is a synthetic peptide designed for use in combination with anti-KDR antibody (Catalog #: AVARP20010_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
VEGFR2
Reaktivität: Human, Maus, Ratte, Schwein, Schaf
Wirt: Synthetic
BP
Applikationshinweise
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
VEGFR2/CD309 (VEGFR2)
(VEGF Receptor 2 (VEGFR2))
Hintergrund
KDR is the receptor for VEGF or VEGFC. It has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Alias Symbols: CD309, FLK1, VEGFR, VEGFR2
Protein Interaction Partner: SHC2,VEGFA,VEGFA,VEGFA,VEGFC,ACP1,ANXA5,ATR,BMX,CAV1,CBL,CDH5,COL18A1,CRK,CSF2RB,CTNNB1,DNM2,FIGF,FLT1,FLT4,FRS2,FYN,GNA11,GNAQ,GRB10,GRB2,HSP90AA1,IQGAP1,ITGB3,KDR,NCK1,NRP1,P2RY2,PLCG1,PLCG2,PTPN11,PTPN6,RASA1,SH2D2A,SHB,SHC1,SHC2,SRC,STAT1,SYNGAP1,TIMP3,VEGFA,VEGFC,YES1,ACP1,ANXA5,CBL,CDH5,COL18A1,FIGF,FLT1,GRB10,GRB2,PLCG1,PLXNA1,RASA1,SHB,SHC1,SHC2,VEGFA